Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?

    qihua he
    qihua he
    xusen zou
    xusen zou
    lindsey hamblin
    lindsey hamblin

    Annals of translational medicine, Volume 3, Issue 14, 2015.

    Cited by: 0|Bibtex|Views2|Links
    WOS

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments